TSC2/mTORC1 signaling controls Paneth and goblet cell differentiation in the intestinal epithelium

Cell Death and Disease

Volumn 6, Issue , 2015, Pages

  Zhou, Y ^a   Rychahou, P ^a   Wang, Q ^a   Weiss, H L ^a   Evers, B M ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MUCIN 2; NOTCH RECEPTOR; RAPAMYCIN; TRANSCRIPTION FACTOR HES 1; TUBERIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; HES1 PROTEIN, MOUSE; HOMEODOMAIN PROTEIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; GOBLET CELL; HT 29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE CRYPT; INTESTINE EPITHELIUM; MOUSE; NONHUMAN; PANETH CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BIOLOGICAL MODEL; CELL LINEAGE; CYTOLOGY; INTESTINE MUCOSA; METABOLISM; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE;

MUS; MUS MUSCULUS;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL LINEAGE; GOBLET CELLS; HOMEODOMAIN PROTEINS; HUMANS; INTESTINAL MUCOSA; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MULTIPROTEIN COMPLEXES; PANETH CELLS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84923129388     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.588     Document Type: Article

References (55)

1. Yeung TM, Chia LA, Kosinski CM, Kuo CJ. Regulation of self-renewal and differentiation by the intestinal stem cell niche. Cell Mol Life Sci 2011; 68: 2513-2523.
2. De Mey JR, Freund JN. Understanding epithelial homeostasis in the intestine: an old battlefield of ideas, recent breakthroughs and remaining controversies. Tissue Barriers 2013; 1: e24965.
3. Gunther C, Neumann H, Neurath MF, Becker C. Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium. Gut 2013; 62: 1062-1071.
4. Gersemann M, Wehkamp J, Stange EF. Innate immune dysfunction in inflammatory bowel disease. J Intern Med 2012; 271: 421-428.
5. Hammoud SS, Cairns BR, Jones DA. Epigenetic regulation of colon cancer and intestinal stem cells. Curr Opin Cell Biol 2013; 25: 177-183.
6. Clark JA, Doelle SM, Halpern MD, Saunders TA, Holubec H, Dvorak K et al. Intestinal barrier failure during experimental necrotizing enterocolitis: protective effect of EGF treatment. Am J Physiol Gastrointest Liver Physiol 2006; 291: G938-G949.
7. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372: 657-668.
8. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 2002; 99: 13571-13576.
9. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15: 807-826.
10. Makky K, Tekiela J, Mayer AN. Target of rapamycin (TOR) signaling controls epithelial morphogenesis in the vertebrate intestine. Dev Biol 2007; 303: 501-513.
11. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 2008; 22: 239-251.
12. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22.
13. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 2006; 7: 678-689.
14. Stanger BZ, Datar R, Murtaugh LC, Melton DA. Direct regulation of intestinal fate by Notch. Proc Natl Acad Sci USA 2005; 102: 12443-12448.
15. Jensen J, Pedersen EE, Galante P, Hald J, Heller RS, Ishibashi M et al. Control of endodermal endocrine development by Hes-1. Nat Genet 2000; 24: 36-44.
16. Ueo T, Imayoshi I, Kobayashi T, Ohtsuka T, Seno H, Nakase H et al. The role of Hes genes in intestinal development, homeostasis and tumor formation. Development 2012; 139: 1071-1082.
17. Rodilla V, Villanueva A, Obrador-Hevia A, Robert-Moreno A, Fernandez-Majada V, Grilli A et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci USA 2009; 106: 6315-6320.
18. Zhou Y, Wang Q, Weiss HL, Evers BM. Nuclear factor of activated T-cells 5 increases intestinal goblet cell differentiation through an mTOR/Notch signaling pathway. Mol Biol Cell 2014; 25: 2882-2890.
19. Zhou Y, Wang Q, Guo Z, Weiss HL, Evers BM. Nuclear factor of activated T-cell c3 inhibition of mammalian target of rapamycin signaling through induction of regulated in development and DNA damage response 1 in human intestinal cells. Mol Biol Cell 2012; 23: 2963-2972.
20. Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 1999; 104: 687-695.
21. Bhatia B, Northcott PA, Hambardzumyan D, Govindarajan B, Brat DJ, Arbiser JL et al. Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization. Cancer Res 2009; 69: 7224-7234.
22. Govindarajan B, Brat DJ, Csete M, Martin WD, Murad E, Litani K et al. Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissuespecific tuberous sclerosis phenotype in the skin and brain. J Biol Chem 2005; 280: 5870-5874.
23. Chevere-Torres I, Kaphzan H, Bhattacharya A, Kang A, Maki JM, Gambello MJ et al. Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the DeltaRG mouse model of tuberous sclerosis complex. Neurobiol Dis 2012; 45: 1101-1110.
24. Shao J, Evers BM, Sheng H. Roles of phosphatidylinositol 3'-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 2004; 64: 229-235.
25. Hardiman KM, Liu J, Feng Y, Greenson JK, Fearon ER. Rapamycin inhibition of polyposis and progression to dysplasia in a mouse model. PLoS One 2014; 9: e96023.
26. Schneider MR, Dahlhoff M, Horst D, Hirschi B, Trulzsch K, Muller-Hocker J et al. A key role for E-cadherin in intestinal homeostasis and Paneth cell maturation. PLoS One 2010; 5: e14325.
27. Vooijs M, Liu Z, Kopan R. Notch: architect, landscaper, and guardian of the intestine. Gastroenterology 2011; 141: 448-459.
28. VanDussen KL, Carulli AJ, Keeley TM, Patel SR, Puthoff BJ, Magness ST et al. Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. Development 2012; 139: 488-497.
29. Pear WS. New roles for Notch in tuberous sclerosis. J Clin Invest 2010; 120: 84-87.
30. Ma J, Meng Y, Kwiatkowski DJ, Chen X, Peng H, Sun Q et al. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest 2010; 120: 103-114.
31. Karbowniczek M, Zitserman D, Khabibullin D, Hartman T, Yu J, Morrison T et al. The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development. J Clin Invest 2010; 120: 93-102.
32. Lamming DW, Sabatini DM. A Central role for mTOR in lipid homeostasis. Cell Metab 2013; 18: 465-469.
33. Dai J, Bercury KK, Macklin WB. Interaction of mTOR and Erk1/2 signaling to regulate oligodendrocyte differentiation. Glia 2014; 62: 2096-2109.
34. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149: 274-293.
35. Yilmaz OH, Katajisto P, Lamming DW, Gultekin Y, Bauer-Rowe KE, Sengupta S et al. mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature 2012; 486: 490-495.
36. Turgeon N, Blais M, Gagne JM, Tardif V, Boudreau F, Perreault N et al. HDAC1 and HDAC2 restrain the intestinal inflammatory response by regulating intestinal epithelial cell differentiation. PLoS One 2013; 8: e73785.
37. Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ et al. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg 2010; 210: 776-768.
38. Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, Qiu S et al. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res 2009; 15: 7207-7216.
39. Pajvani UB, Qiang L, Kangsamaksin T, Kitajewski J, Ginsberg HN, Accili D. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat Med 2013; 19: 1054-1060.
40. Kapuria S, Karpac J, Biteau B, Hwangbo D, Jasper H. Notch-mediated suppression of TSC2 expression regulates cell differentiation in the Drosophila intestinal stem cell lineage. PLoS Genet 2012; 8: e1003045.
41. Shorning BY, Zabkiewicz J, McCarthy A, Pearson HB, Winton DJ, Sansom OJ et al. Lkb1 deficiency alters goblet and paneth cell differentiation in the small intestine. PLoS One 2009; 4: e4264.
42. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 2009; 196: 65-80.
43. Gersemann M, Stange EF, Wehkamp J. From intestinal stem cells to inflammatory bowel diseases. World J Gastroenterol 2011; 17: 3198-3203.
44. Salzman NH, Bevins CL. Dysbiosis-a consequence of Paneth cell dysfunction. Semin Immunol 2013; 25: 334-341.
45. Shirazi T, Longman RJ, Corfield AP, Probert CS. Mucins and inflammatory bowel disease. Postgrad Med J 2000; 76: 473-478.
46. Einerhand AW, Renes IB, Makkink MK, van der Sluis M, Buller HA, Dekker J. Role of mucins in inflammatory bowel disease: important lessons from experimental models. Eur J Gastroenterol Hepatol 2002; 14: 757-765.
47. Deng L, Zhou JF, Sellers RS, Li JF, Nguyen AV, Wang Y et al. A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am J Pathol 2010; 176: 952-967.
48. Yin H, Li X, Zhang B, Liu T, Yuan B, Ni Q et al. Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis. Immunology 2013; 139: 494-502.
49. Garcia-Maurino S, Alcaide A, Dominguez C. Pharmacological control of autophagy: therapeutic perspectives in inflammatory bowel disease and colorectal cancer. Curr Pharm Des 2012; 18: 3853-3873.
50. Dumortier J, Lapalus MG, Guillaud O, Poncet G, Gagnieu MC, Partensky C et al. Everolimus for refractory Crohn's disease: a case report. Inflamm Bowel Dis 2008; 14: 874-877.
51. Massey DC, Bredin F, Parkes M. Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 2008; 57: 1294-1296.
52. Wang Q, Wang X, Evers BM. Induction of cIAP-2 in human colon cancer cells through PKC delta/NF-kappa B. J Biol Chem 2003; 278: 51091-51099.
53. Wang Q, Zhou Y, Wang X, Evers BM. Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. Oncogene 2006; 25: 43-50.
54. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotech 2004; 22: 326-330.
55. Wang Q, Zhou Y, Rychahou P, Liu C, Weiss HL, Evers BM. NFAT5 represses canonical Wnt signaling via inhibition of beta-catenin acetylation and participates in regulating intestinal cell differentiation. Cell Death Dis 2013; 4: e671.